Patients' and physicians' perspectives on pharmacogenetic testing

被引:94
|
作者
Rogausch, A
Prause, D
Schallenberg, A
Brockmöller, J
Himmel, W
机构
[1] Univ Gottingen, Dept Gen Practice Family Med, D-37073 Gottingen, Germany
[2] Univ Gottingen, Dept Clin Pharmacol, D-37073 Gottingen, Germany
关键词
attitude of health personnel; delivery of healthcare; ethics; patient acceptance of healthcare; pharmacogenetics;
D O I
10.2217/14622416.7.1.49
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: The integration of pharmacogenetic testing into routine care will, in part, depend upon the patients' and physicians' acceptance of these tests. Empirical data regarding patients' and physicians' views on pharmacogenetic testing are lacking. Objectives: To explore patients' and physicians' perspectives on the potential implications of pharmacogenetic testing, particularly focusing on asthma, and to analyze the possible determinants of their expectations, hopes and fears. Methods: We conducted telephone interviews with patients with asthma or chronic obstructive pulmonary disease taking part in a larger pharmacogenetic study, in addition to general practitioners (GPs) from a different region in Germany. A total of 328 patients and 378 GPs were invited to participate. Determinants of their attitudes toward pharmacogenetic testing were assessed using logistic regression analysis. Results: Informed consent to participate in this study was given by 196 patients (60%) and 106 GPs (28%). Most patients (96%) and physicians (52%) appreciated the availability of pharmacogenetic tests for a disease such as asthma. Approximately a third of the patients worried about potential unfavorable test results (35%) and violation of privacy (36%). Female patients were more likely to have a fearful attitude (odds ratio [OR]=2.85; 95% confidence interval [CI]=1.58-5.12). Younger patients were generally more likely to be hopeful about the usefulness of pharmacogenetic testing (OR=2.12; CI=1.01-4.46). The GPs' concerns were mainly related to the possibility that patients might either be put under pressure to be tested (72%) or be disadvantaged at private health insurance agencies (61%). The nature of the responsible institution, the clarity of the research aim and explicit informed consent from patients influenced a physicians' decision regarding whether to support a pharmacogenetic study. Conclusion: The concerns of patients and GPs differ somewhat with respect to negative psychosocial consequences, discrimination or violation of privacy. Development of information for physicians and patients would be helpful in preventing unrealistic fears or hopes.
引用
收藏
页码:49 / 59
页数:11
相关论文
共 50 条
  • [1] Patients' Perspectives on Psychiatric Pharmacogenetic Testing
    Liko, Ina
    Lai, Erika
    Griffin, Rachel J.
    Aquilante, Christina L.
    Lee, Yee Ming
    [J]. PHARMACOPSYCHIATRY, 2020, 53 (06) : 256 - 261
  • [2] National survey of physicians' perspectives on pharmacogenetic testing in solid organ transplantation
    Deininger, Kimberly M.
    Tsunoda, Shirley M.
    Hirsch, Jan D.
    Anderson, Heather
    Lee, Yee Ming
    McIlvennan, Colleen K.
    Page, Robert L.
    Tran, Jacinda N.
    Aquilante, Christina L.
    [J]. CLINICAL TRANSPLANTATION, 2020, 34 (10)
  • [3] FDA perspectives on pharmacogenetic testing
    Harper, CC
    Philip, R
    Robinowitz, M
    Gutman, SI
    [J]. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2005, 5 (05) : 643 - 648
  • [4] Pharmacogenetic testing in primary care practice: opinions of physicians, pharmacists and patients
    Frigon, Marie-Pier
    Blackburn, Marie-Eve
    Dubois-Bouchard, Camelia
    Gagnon, Ann-Lorie
    Tardif, Suzie
    Tremblay, Karine
    [J]. PHARMACOGENOMICS, 2019, 20 (08) : 589 - 598
  • [5] Physicians' attitudes toward pharmacogenetic testing before and after pharmacogenetic education
    Luzum, Jasmine A.
    Luzum, Matthew J.
    [J]. PERSONALIZED MEDICINE, 2016, 13 (02) : 119 - 127
  • [6] Physicians' Attitudes and Ethical Obligations to Pharmacogenetic Testing
    Muflih, Suhaib
    Al-Husein, Belal A.
    Karasneh, Reema
    Alzoubi, Karem H.
    [J]. JOURNAL OF MULTIDISCIPLINARY HEALTHCARE, 2020, 13 : 249 - 258
  • [7] Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery
    Powell, Graham
    Holmes, Emily A. F.
    Plumpton, Catrin O.
    Ring, Adele
    Baker, Gus A.
    Jacoby, Ann
    Pirmohamed, Munir
    Marson, Anthony G.
    Hughes, Dyfrig A.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (05) : 1149 - 1159
  • [8] The perspectives of pharmacogenetic testing implementation in patients with suspected primary pulmonary hypertension
    Hromnikova, N.
    Babiak, E.
    Pivackova, L. B.
    Klimas, J.
    Krenek, P.
    Goncalvesova, E.
    Luknar, M.
    Doka, G.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2023, 45 (03) : 796 - 796
  • [9] Physicians' opinions following pharmacogenetic testing for psychotropic medication
    Walden, Lucas M.
    Brandl, Eva J.
    Changasi, Amtul
    Sturgess, Jessica E.
    Soibel, Alexander
    Notario, Janna Fe D.
    Cheema, Sheraz
    Braganza, Nicole
    Marshe, Victoria S.
    Freeman, Natalie
    Tiwari, Arun K.
    Kennedy, James L.
    Mueller, Daniel J.
    [J]. PSYCHIATRY RESEARCH, 2015, 229 (03) : 913 - 918
  • [10] Primary care physicians' knowledge of and experience with pharmacogenetic testing
    Haga, S. B.
    Burke, W.
    Ginsburg, G. S.
    Mills, R.
    Agans, R.
    [J]. CLINICAL GENETICS, 2012, 82 (04) : 388 - 394